The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Global Epidemiology of Mucormycosis
Open accessAbstract
Mucormycosis is an angio-invasive fungal infection, associated with high morbidity and mortality. A change in the epidemiology of mucormycosis has been observed in recent years with the rise in incidence, new causative agents and susceptible population. The rise has been perceived globally, but it is very high in the Asian continent. Though diabetes mellitus overshadow all other risk factors in Asia, post-tuberculosis and chronic renal failure have emerged as new risk groups. The rhino-cerebral form of mucormycosis is most commonly seen in patients with diabetes mellitus, whereas, pulmonary mucormycosis in patients with haematological malignancy and transplant recipients. In immunocompetent hosts, cutaneous mucormycosis is commonly seen following trauma. The intriguing clinical entity, isolated renal mucormycosis in immunocompetent patients is only reported from China and India. A new clinical entity, indolent mucormycosis in nasal sinuses, is recently recognized. The causative agents of mucormycosis vary across different geographic locations. Though Rhizopus arrhizus is the most common agent isolated worldwide, Apophysomyces variabilis is predominant in Asia and Lichtheimia species in Europe. The new causative agents, Rhizopus homothallicus, Mucor irregularis, and Thamnostylum lucknowense are reported from Asia. In conclusion, with the change in epidemiology of mucormycosis country-wise studies are warranted to estimate disease burden in different risk groups, analyse the clinical disease pattern and identify the new etiological agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“After the inclusion of Indian data, the estimate of mucormycosis rose to 910,000 cases globally [23,24].”
BackgroundRibes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Epidemiology and Clinical Manifestations of Mucormycosis
Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir866 · Cited by 1,452
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S. C.-A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.011 · Cited by 1,082
Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Lass-Florl, C., Bouza, E., Klimko, N., Gaustad, P., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03456.x · Cited by 748
Cited by
Global incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.019 · Cited by 1,102
Epidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis
John, T. M., Jacob, C. N., & Kontoyiannis, D. P. (2021) · Journal of Fungi · doi:10.3390/jof7040298 · Cited by 524
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Patel, A., Agarwal, R., Rudramurthy, S. M., Shevkani, M., Xess, I., Sharma, R., Savio, J., Sethuraman, N., Madan, S., Shastri, P., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2709.210934 · Cited by 479
Self-citationThe emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
Hoenigl, M., Seidel, D., Carvalho, A., Rudramurthy, S. M., Arastehfar, A., Gangneux, J.-P., Nasir, N., Bonifaz, A., Araiza, J., Klimko, N., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00237-8 · Cited by 443
Self-citationEpidemiology of Mucormycosis in India
Prakash, H., & Chakrabarti, A. (2021) · Microorganisms · doi:10.3390/microorganisms9030523 · Cited by 441
Self-citationSen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., et al. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1565_21 · Cited by 418
Patel, A., Kaur, H., Xess, I., Michael, J. S., Savio, J., Rudramurthy, S., Singh, R., Shastri, P., Umabala, P., Sardana, R., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.021 · Cited by 405
Self-citationCOVID‐19‐associated mucormycosis: An updated systematic review of literature
Pal, R., Singh, B., Bhadada, S. K., Banerjee, M., Bhogal, R. S., Hage, N., & Kumar, A. (2021) · Mycoses · doi:10.1111/myc.13338 · Cited by 289
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Chang, Z., & Heitman, J. (2019) · mBio · doi:10.1128/mbio.02579-19 · Cited by 202
“Mucormycosis encompasses a broad range of infections from cutaneous infections to invasive systemic disease, which can lead to rates of mortality greater than 90% (2, 3).”
Background
Metadata
- Authors
- Prakash, H., & Chakrabarti, A.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2019-03-21
- Volume
- 5
- Issue
- 1
- Pages
- 26
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W2923177230
- Cited by
- 938
- References
- 136
- FWCI
- 85.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.